EMIT II Plus Propoxyphene Assay
The EMIT® II Plus Propoxyphene Assay is intended for the qualitative and semiquantitative analyses of propoxyphene in human urine at a cutoff level of 300 ng/mL.
EMIT II Plus Propoxyphene Assay
Screen for illicit use of DARVOCET
Features & Benefits
Although marketed drugs such as DARVON and DARVOCET were pulled from the market by the FDA in 2011, there is still illicit use in the U.S., a situation similar to methaqualone and QUAALUDE. The EMIT® II Plus Propoxyphene Assay detects propoxyphene and propoxyphene salts, such as propoxyphene napsylate, in human urine. It also detects norpropoxyphene (N-desmethyldextropropoxyphene), the major urinary metabolite of propoxyphene.
The EMIT II Plus Propoxyphene Assay provides:
- Excellent precision—all within-lab (total) CVs ≤1.0% or less across the assay range
- Ready-to-use liquid reagents, calibrators, and controls
- >98% agreement with the reference method (GC/MS)
Applications are available for the Viva-Jr®, Viva-E®, Viva-ProE®, V-Twin® drug testing systems; AU® Series analyzers; Dimension® Integrated Chemistry Systems; and Dimension Vista® Intelligent Lab Systems.
Technical Specifications
EMIT II Plus Propoxyphene Performance
Assay Principle | Homogeneous Enzyme Multiplied Immonoassay (EMIT) |
Cut-off | 300 ng/mL |
Sample | Urine |
Reagent Stability | Unopened: until expiration date. Onboard instrument: up to 4 weeks |
Calibration Frequency | As indicated by control results |